Impact of medication therapy management on pharmacotherapy safety in an intensive care unit
- 74 Downloads
Background Drug-related problems are mostly preventable or predictable circumstances that may impact on health outcomes. Clinical pharmacy activities such as medication therapy management can identify and solve these problems, with potential to improve medication safety and effectiveness. Objective To evaluate ability of medication therapy management service to detect drug-related problems and prevent adverse drug events. This study also aimed to assess the risk factors for drugrelated problem occurrence. Setting Medical intensive care unit of a public tertiary hospital in Brazil. Methods Patients were evaluated by a clinical pharmacist, who provided medication therapy management service. Detected drug-related problems were categorized according to the Pharmaceutical Care Network Europe methodology and analyzed in multinomial regression to identify risk factors. Main outcome measure Potential risk factors for drug-related problem occurrence. Results The proposed medication therapy management service allowed detection of 170 drug-related problems that had potential to reach patients causing harm and other 50 unavoidable adverse events. Drug-related problems identified were more often associated with antibacterial use, caused by improper combinations or inadequate drug dosage. These problems required interventions that were accepted by the multidisciplinary team, resulting in more than 85% adherence and total problem solving. Main risk factors identified were previous diagnosis of kidney injury (OR = 8.38), use of midazolam (OR = 7.96), furosemide (OR = 5.87) and vancomycin (OR = 4.82). Conclusion Medication therapy management proved to be an effective method not only for drug-related problem detection, but also for adverse drug event prevention, contributing to improve patient safety.
KeywordsAdverse drug events Brazil Clinical pharmacists Drug-related problems Medication therapy management PCNE DRP-classification
The authors thank Prof. Nathalie de L. S. Dewulf and Prof. Ana Elisa B. C. Silva for their suggestions, support and encouragement.
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001—grants AUXPE 1665/2016 and Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG).
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 5.Pharmaceutical Care Network Europe Foundation. PCNE Classification for drug related problems version 7.0. 2016. http://www.pcne.org/upload/files/152_PCNE_classification_V7-0.pdf. Accessed 02 Aug 2018.
- 17.Vincent JL, Moreno R, Takala J, Willatts S, DeMendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.CrossRefGoogle Scholar
- 19.World Health Organization. Medication without harm—global patient safety challenge on medication safety. Geneva: World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/255263/1/WHO-HIS-SDS-2017.6-eng.pdf?ua=1. Accessed 02 Aug 2018.
- 36.Franco Sereno MT, Pérez Serrano R, Ortiz Díaz-Miguel R, Espinosa González MC, Abdel-HadiÁlvarez H, Ambrós Checa A, et al. Pharmacist adscription to intensive care: generating synergies. Med Intensiva. 2018;S0210-5691(18):30052-4.Google Scholar